Advertisement

Topics

QIAGEN’s QuantiFERON-TB® Gold Plus Gains Endorsement for Latent Tuberculosis Screening in Immigration

06:00 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
International Panel Physicians Association selects QFT-Plus for its proven value in diagnosing latent TB infection QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QuantiFERON-TB® Gold Plus (...

Other Sources for this Article

QIAGEN
Investor Relations
John Gilardi, +49 2103 29 11711
e-mail: ir@QIAGEN.com
or
Public Relations
Dr. Thomas Theuringer, +49 2103 29 11826
e-mail: pr@QIAGEN.com

NEXT ARTICLE

More From BioPortfolio on "QIAGEN’s QuantiFERON-TB® Gold Plus Gains Endorsement for Latent Tuberculosis Screening in Immigration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Tuberculosis TB
Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. Over nine million new cases of TB, and nearly two million deaths from TB, are estimated to occur around the world every year, and new inf...